NAFLD and NASH in HIV-patients, prevalence and risk factors.

NAFLD and NASH in HIV-patients, prevalence and risk factors. - NAFLD and NASH in HIV-patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON46464

Enrollment

1000

Registered

2018-05-17

Start date

2017-11-01

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fatty liver liver steatosis

Interventions

Fibroscan + CAP measurement. The fibroscan non-invasively measures the elasticity of the liver, allowing the degree of fibrosis to be determined. With the same device a CAP measurement is performe

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Unselected adult HIV-infected patients visiting the outpatient clinic of a major HIV reference centers in the Netherland (Erasmus MC).

Exclusion criteria

Exclusion criteria: * Excessive alcohol consumption (> 5 glasses per day) * (History of) hepatocellular carcinoma * Liver transplant in the past * Contraindications fibroscan (pregnancy, pacemaker) * Other liver diseases (autoimmune hepatitis, hemochromatosis, Wilson's disease). Note: Chronic hepatitis B and C are not exclusionary criteria.

Design outcomes

Primary

Measure	Time frame
1. Prevalence of NASH in our HIV-infected population compared to what is known from other HIV populations (6-11%).	—

Secondary

Measure	Time frame
2. Risk factors for NASH 3. Prevalence of NALFD in our HIV-infected population compared to what is known from other HIV populations (30-55%). 4. Risk factors for NALFD	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)